Mission & Topics * Membership Information & How to Join * Terms & Conditions
Archive of Past Roundtable Discussions
Communicating Risk in DTC Advertising
Date: Thursday, 13 April 2006
Time: 12:00 PM Eastern Time
Background
The Coalition for Healthcare Communication (CHC) — comprised of major advertising, marketing and PR organizations, including the American Association of Advertising Agencies, the Association of National Advertisers, and the Public Relations Society of America — filed a Citizen Petition with the Food and Drug Administration on March 31, 2006, asking the FDA to formulate new rules governing consumer advertising of prescription drugs.
The proposal calls for the elimination of specific risk information in print and broadcast DTC (direct to consumer) advertising. You can read more about this in a recent post to Pharma Marketing Blog: “DTC without the Risk.”
Moderator: John Mack
Participants:
- Jack Angel, Coalition for Healthcare Communication
- Jack Barrette, Yahoo!
- Neil Gray, Healthcare Trends & Strategies
- Harry Sweeney, Coalition for Healthcare Communication
Survey:
To prepare for this conference call, participants were asked to respond to an online survey regarding the CHC petition. This survey asks respondents opinion on:
- The merit of the CHC proposal
- The likelihood that the FDA will adopt CHC’s suggestions
After completing the survey you will be able to see a summary of results (de-identified, excludes open-ended responses and comments that may identify the respondent). You can also use filters to examine results from different subsets of respondents (e.g., pharma company employees vs. non-pharma people, etc.).
Article:
Communicating Risk: Let the Dialog Begin This article presents a lightly edited transcript of the Pharma Marketing Roundtable discussion that included CHC representatives. Also included are excerpts from news stories about the CHC petition, results of a Pharma Marketing News online survey, and a collection of comments from survey respondents and bloggers.
Topics covered include:
- Excerpts from Pharma Marketing Blog (“DTC without the Risk”)
- Pfizer’s Way of Communicating Risk
- Commentary from Pharma Marketing Roundtable Members
Order the Full Article Reprint – $9.95
